

# FRESENIUS MEDICAL

ISIN: DE0005785802 WKN: 578580 Asset Class: Stock

|  |  |
|--|--|
| <b>Company</b>   | 2024/06/06 17:35:20  |
|  | <b>Price</b><br><b>39.39</b><br>EUR                                |
|  | <b>Difference</b> <span style="color: green;">▲</span> 0.56%(0.22) |



## Contact Details

FRESENIUS MEDICAL CARE AG  
 Tel: +49-6172-609-0  
 Fax: +  
 Else-Kröner-Strasse 1  
 61352 Bad Homburg  
 Web: <http://www.freseniusmedicalcare.com/de>  
 E-mail: [marketing.international@freseniusmedicalcare.com](mailto:marketing.international@freseniusmedicalcare.com)

## Company Profile

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023           |                        | 2022           |                        | 2021           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 8,565,168,000  |                        | 8,056,523,000  |                        | 7,812,639,000  |                        |
| <b>Common stock capital</b>           |                | 293,413,000            |                | 293,413,000            |                | 293,004,000            |
| <b>Fixed assets</b>                   | 25,364,640,000 |                        | 27,697,591,000 |                        | 26,553,919,000 |                        |
| <b>Equity capital of a company</b>    |                | 14,826,535,000         |                | 15,449,179,000         |                | 13,979,037,000         |
| <b>Cash and cash equivalents</b>      | 1,403,492,000  |                        | 1,273,787,000  |                        | 1,481,655,000  |                        |
| <b>Accrued liabilities</b>            |                | 839,624,000            |                | 709,689,000            |                | 965,914,000            |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 6,111,590,000          |                | 6,467,314,000          |                | 7,257,634,000          |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 12,991,683,000         |                | 13,837,621,000         |                | 13,129,887,000         |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 912,923,000            |                | 1,015,785,000          |                | 560,769,000            |
| <b>Total assets</b>                   | 33,929,808,000 | 33,929,808,000         | 35,754,114,000 | 35,754,114,000         | 34,366,558,000 | 34,366,558,000         |

## Balance notes

|                            | 2023    | 2022    | 2021    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | IFRS    | IFRS    | IFRS    |
| <b>Employees</b>           | 119,845 | 128,044 | 122,909 |
| <b>Equity ratio</b>        | 47.25%  | 47.29%  | 44.40%  |
| <b>Debt-equity ratio</b>   | 111.63% | 111.45% | 125.22% |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 32.98% | 28.19% | 23.85% |

# FRESENIUS MEDICAL

ISIN: DE0005785802 WKN: 578580 Asset Class: Stock

## Income statement

|  | 2023           | 2022           | 2021           |
|--|----------------|----------------|----------------|
| <b>Turnover</b>  | 19,454,117,000 | 19,395,319,000 | 17,618,410,000 |
| <b>Net income</b>  | 498,997,000    | 673,405,000    | 969,308,000    |
| <b>EBIT</b>  | 1,236,724,000  | 1,435,794,000  | 1,764,011,000  |
| <b>Operating income before taxes</b>                                 | 911,230,000    | 1,152,720,000  | 1,479,686,000  |
| <b>Cash Flow</b>   | 2,628,801,000  | 2,167,379,000  | 2,489,498,000  |
| <b>Net interest income</b>   | -325,494,000   | -283,074,000   | -284,325,000   |
| <b>Research and development expenses</b>                             | 231,970,000    | 228,624,000    | 220,782,000    |
| <b>Income taxes</b>  | 300,557,000    | 324,954,000    | 352,833,000    |
| <b>Result from investments in subsidiaries, associates and other</b> | 121,785,000    | 66,559,000     | 92,175,000     |
| <b>Revenues per employee</b>   | 162,327        | 151,474        | 143,345        |

## Board of Directors

|                      |                               |
|----------------------|-------------------------------|
| Michael Sen          | Chairman of Supervisory Board |
| A. Sorensen          | Member of Supervisory Board   |
| Manuela Stauss-Grabo | Member of Supervisory Board   |
| Marcus Kuhnert       | Member of Supervisory Board   |
| Beate Haßdenteufel   | Member of Supervisory Board   |
| Frank Prescher       | Member of Supervisory Board   |
| Pascale Witz         | Member of Supervisory Board   |
| Ralf Erkens          | Member of Supervisory Board   |
| Regina Karsch        | Member of Supervisory Board   |
| Sara Hennicken       | Member of Supervisory Board   |
| Shervin Korangy      | Member of Supervisory Board   |
| Stefanie Lang        | Member of Supervisory Board   |

## Members of Management Board

|                                     |                               |
|-------------------------------------|-------------------------------|
| Helen Ping Giza                     | Chairman of Managing Board    |
| Frank Maddux                        | Member of Executive Committee |
| Craig Cordola                       | Member of Executive Committee |
| Jörg Häring                         | Member of Executive Committee |
| M.D.,Ph.D. Katarzyna Mazur-Hofsaess | Member of Executive Committee |
| Martin Fischer                      | Member of Executive Committee |